このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

局所発作の成人におけるセノバメイト (BLESS)

局所発作の成人におけるセノバメイト:現実世界の多施設観察イタリア人

The BLESS Study contributes to filling this information gap by collecting data from the Italian clinical practice and the Compassionate Use Program, to better characterize the clinical profile of cenobamate describing its effectiveness, safety and tolerability in adult patients diagnosed with uncontrolled focal epilepsy despite the use of at least two antiepileptic medicinal products.

調査の概要

状態

完了

詳細な説明

The main objective of the study is to describe the effectiveness of adjunctive cenobamate treatment in adult patients with uncontrolled focal epilepsy in Italy, overall and according to age class, setting of cenobamate treatment, cenobamate final target daily dose prescribed, and number of concomitant Anti Seizure Medications (ASMs). This will be assessed by intra-patient percent change and achievement of a ≥50% reduction in the seizure frequency from the pre-treatment baseline over a period of 52 weeks.

研究の種類

観察的

入学 (実際)

936

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Bari
      • Bari、Bari、イタリア、70124
        • Policlinico di Bari
    • Catanzaro
      • Catanzaro、Catanzaro、イタリア、88100
        • Università degli Studi di Catanzaro "Magna Graecia"
    • Isernia
      • Pozzilli、Isernia、イタリア、86077
        • IRCCS Neuromed
    • Pavia
      • Pavia、Pavia、イタリア、27100
        • Fondazione Istituto Neurologico Casimiro Mondino
    • Roma
      • Roma、Roma、イタリア、00128
        • Campus Bio-Medico
      • Roma、Roma、イタリア、00161
        • Policlinico Umberto I
    • Torino
      • Torino、Torino、イタリア、10153
        • Humanitas Gradenigo
    • Treviso
      • Conegliano、Treviso、イタリア、31015
        • Associazione La Nostra Famiglia - IRCCS Eugenio Medea
    • Udine
      • Udine、Udine、イタリア、33100
        • Azienda Sanitaria Universitaria (A.O.U.) Integrata
    • Vicenza
      • Vicenza、Vicenza、イタリア、36100
        • Ospedale San Bortolo

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~99年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

サンプリング方法

確率サンプル

調査対象母集団

Adult patients diagnosed with focal epilepsy uncontrolled despite the use of at least two antiepileptic medicinal products, treated with adjunctive cenobamate in Italy. A single cohort of patients will be involved in the study, enrolling both subjects who initiated cenobamate treatment in accordance with the current clinical practice, and subjects previously included in the cenobamate Compassionate Use Programme in Italy, provided that they fulfil all of the eligibility criteria listed below

説明

Inclusion Criteria:

  • Age ≥18 years at the time of cenobamate treatment initiation
  • Male or female patients
  • Patients diagnosed with focal epilepsy uncontrolled despite a history of treatment with at least two antiepileptic medicinal products at the time of cenobamate treatment initiation in agreement with the Summary of Product Characteristics (SmPC)
  • Patients who at enrolment had received at least 12 weeks (titration period up to the initial recommended target dose of 200 mg daily completed) but no more than 52 weeks of cenobamate as adjunctive treatment of focal-onset seizures with or without secondary generalization
  • Patients with available retrospective data in medical charts and seizure diaries, including information about baseline seizure frequency prior to cenobamate treatment initiation
  • Patients who gave written informed consent to take part into the study and personal data processing consent following local regulation.
  • Patients who received adjunctive cenobamate for at least 12 weeks and discontinued permanently treatment before enrolment will also be included in the study-

Exclusion Criteria:

  • Patients diagnosed with familial short-QT syndrome
  • Patients affected by hypersensitivity to the active substance cenobamate or to any of the excipients (e.g., lactose monohydrate)
  • Patients with history of severe drug-induced hypersensitivity reaction, including (but not limited to) drug reaction with eosinophilia and systemic symptoms (DRESS), and Stevens Johnson syndrome
  • Patients enrolled in a clinical trial in which treatments for epilepsy are managed through a study protocol
  • Patient unable to read and write in Italian language and to autonomously fill in questionnaires and scales
  • Patients with a known pregnancy or who are breast-feeding from cenobamate treatment initiation till enrolment visit.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 観測モデル:OTHER
  • 時間の展望:PROSPECTIVE

コホートと介入

グループ/コホート
Adult patients diagnosed treated with adjunctive cenobamate in Italy.

Adult patients diagnosed with focal epilepsy uncontrolled despite the use of at least two antiepileptic medicinal products, treated with adjunctive cenobamate in Italy.

A single cohort of patients will be involved in the study, enrolling both subjects who initiated cenobamate treatment in accordance with the current clinical practice, and subjects previously included in the cenobamate Compassionate Use Programme in Italy, provided that they fulfil all of the eligibility criteria listed below

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Absolute frequency of patients achieving a 50 % or greater reduction in the seizure frequency (overall)
時間枠:12, 24 and 52 weeks of cenobamate treatment initiation

Seizure frequency during the baseline and post-baseline assessments was calculated by summing the total number of seizures (all types of seizures) reported in each considered period and dividing by the duration of that period (number of days), excluding days with no available diary data, and multiplying by 28 to normalize to a monthly rate ("monthly seizure frequency").

12, 24 and 52 weeks of cenobamate treatment initiation
Relative frequency of patients achieving a ≥50% (50% or greater) reduction in the seizure frequency (overall)
時間枠:12, 24 and 52 weeks of cenobamate treatment initiation

Seizure frequency during the baseline and post-baseline assessments was calculated by summing the total number of seizures (all types of seizures) reported in each considered period and dividing by the duration of that period (number of days), excluding days with no available diary data, and multiplying by 28 to normalize to a monthly rate ("monthly seizure frequency").

12, 24 and 52 weeks of cenobamate treatment initiation
Intra-patient percent change in the seizure frequency (overall)
時間枠:12, 24 and 52 weeks of cenobamate treatment initiation

Intra-patient percent change from baseline will be defined as [(monthly seizure frequency at post-baseline assessments - monthly seizure frequency at baseline), divided by the monthly seizure frequency at baseline] multiplied by 100.

12, 24 and 52 weeks of cenobamate treatment initiation
Absolute frequency of patients achieving a 50 % or greater reduction in the seizure (stratified)
時間枠:12, 24 and 52 weeks of cenobamate treatment initiation

Seizure frequency during the baseline and post-baseline assessments was calculated by summing the total number of seizures (all types of seizures) reported in each considered period and dividing by the duration of that period (number of days), excluding days with no available diary data, and multiplying by 28 to normalize to a monthly rate ("monthly seizure frequency").

Population will be stratified according to the following:

  • Age class of patient at the time of cenobamate treatment initiation (i.e., <65 years; ≥65 years).
  • Setting of cenobamate treatment initiation (i.e., CUP; current clinical practice).
  • Cenobamate final target daily dose prescribed (i.e., 200 mg; >200 mg).
  • Number of ASMs concomitant with cenobamate (i.e., ≤2 ASMs; >2 ASMs).
12, 24 and 52 weeks of cenobamate treatment initiation
Relative frequency of patients achieving a ≥50% (50% or greater) reduction in the seizure frequency (stratified)
時間枠:12, 24 and 52 weeks of cenobamate treatment initiation

Seizure frequency during the baseline and post-baseline assessments was calculated by summing the total number of seizures (all types of seizures) reported in each considered period and dividing by the duration of that period (number of days), excluding days with no available diary data, and multiplying by 28 to normalize to a monthly rate ("monthly seizure frequency").

Population will be stratified according to the following:

  • Age class of patient at the time of cenobamate treatment initiation (i.e., <65 years; ≥65 years).
  • Setting of cenobamate treatment initiation (i.e., CUP; current clinical practice).
  • Cenobamate final target daily dose prescribed (i.e., 200 mg; >200 mg).
  • Number of ASMs concomitant with cenobamate (i.e., ≤2 ASMs; >2 ASMs).
12, 24 and 52 weeks of cenobamate treatment initiation
Intra-patient percent change in the seizure frequency (stratified)
時間枠:12, 24 and 52 weeks of cenobamate treatment initiation

Intra-patient percent change from baseline will be defined as [(monthly seizure frequency at post-baseline assessments - monthly seizure frequency at baseline), divided by the monthly seizure frequency at baseline] multiplied by 100.

Population will be stratified according to the following:

  • Age class of patient at the time of cenobamate treatment initiation (i.e., <65 years; ≥65 years).
  • Setting of cenobamate treatment initiation (i.e., CUP; current clinical practice).
  • Cenobamate final target daily dose prescribed (i.e., 200 mg; >200 mg).
  • Number of ASMs concomitant with cenobamate (i.e., ≤2 ASMs; >2 ASMs).
12, 24 and 52 weeks of cenobamate treatment initiation

二次結果の測定

結果測定
メジャーの説明
時間枠
Absolute frequency of patients achieving a ≥50%/≥75%/≥90%/=100% sustained reduction in the seizure frequency
時間枠:24 and 52 weeks of cenobamate treatment initiation.

Sustained seizure frequency reduction will be defined as a ≥50%/≥75%/≥90%/=100% reduction in baseline seizure frequency achieved at 12 weeks of cenobamate treatment initiation, that continues (is sustained) without interruption and without cenobamate permanent discontinuation through the observation period until 24 and 52 weeks of cenobamate treatment initiation, respectively.

24 and 52 weeks of cenobamate treatment initiation.
Absolute frequency of patients achieving a ≥75%/≥90%/=100% reduction in the seizure frequency
時間枠:12, 24 and 52 weeks of cenobamate treatment initiation.

Seizure frequency reduction will be defined as a ≥75%/≥90%/=100% reduction in baseline seizure frequency achieved at 12, 24 and 52 weeks of cenobamate treatment initiation, respectively.

12, 24 and 52 weeks of cenobamate treatment initiation.
Relative frequencies of patients achieving a ≥50%/≥75%/≥90%/=100% sustained reduction in the seizure frequency
時間枠:24 and 52 weeks of cenobamate treatment initiation.

Sustained seizure frequency reduction will be defined as a ≥50%/≥75%/≥90%/=100% reduction in baseline seizure frequency achieved at 12 weeks of cenobamate treatment initiation, that continues (is sustained) without interruption and without cenobamate permanent discontinuation through the observation period until 24 and 52 weeks of cenobamate treatment initiation, respectively

24 and 52 weeks of cenobamate treatment initiation.
Relative frequencies of patients achieving a ≥75%/≥90%/=100% reduction in the seizure frequency
時間枠:12, 24 and 52 weeks of cenobamate treatment initiation.

Seizure frequency reduction will be defined as a ≥75%/≥90%/=100% reduction in baseline seizure frequency achieved at 12, 24 and 52 weeks of cenobamate treatment initiation.

12, 24 and 52 weeks of cenobamate treatment initiation.
Absolute frequency of patients with at least one AE
時間枠:Through study completion, an average of 1 year

Absolute frequency of patients treated with cenobamate who experienced at least one AE during the applicable observation period

Through study completion, an average of 1 year
Relative frequency of patients with at least one AE
時間枠:Through study completion, an average of 1 year

Relative frequency of patients treated with cenobamate who experienced at least one AE during the applicable observation period

Through study completion, an average of 1 year
Absolute frequency of patients with at least one ADR
時間枠:Through study completion, an average of 1 year

Absolute frequency of patients treated with cenobamate who experienced at least one ADR during the applicable observation period

Through study completion, an average of 1 year
Relative frequency of patients with at least one ADR
時間枠:Through study completion, an average of 1 year

Relative frequency of patients treated with cenobamate who experienced at least one ADR during the applicable observation period

Through study completion, an average of 1 year
Absolute frequency of patients treated with at least one SAE
時間枠:Through study completion, an average of 1 year

Absolute frequency of patients treated with at least one SAE during the applicable observation period

Through study completion, an average of 1 year
Relative frequency of patients treated with at least one SAE
時間枠:Through study completion, an average of 1 year

Relative frequency of patients treated with at least one SAE during the applicable observation period

Through study completion, an average of 1 year
Health-Related Quality of life (HRQoL)
時間枠:12, 24 and 52 weeks

The Health-Related Quality of life (HRQoL) of patients will be assessed by means of the 31-item Quality Of Life In Epilepsy inventory (QOLIE-31).

The 31-item Quality Of Life In Epilepsy inventory (QOLIE-31) is a patient self-reported instrument that contains 31 items grouped in seven multi-item scales ( "seizure worry", "overall QoL", "emotional well-being", "energy fatigue", "cognitive functioning", "medication effects" and "social functioning"). Different items in the QOLIE-31 have different ranges of precoded numeric values, so the scoring procedure requires conversion from raw, precoded numeric values to scores of 0-100 points, with higher scores reflecting better quality of life. The QOLIE-31 overall score is calculated by summing the product of each scale score times its weight and summing over all scales, according to the instructions obtained from copyright holders.

12, 24 and 52 weeks
Patient Global functioning (CGI-S)
時間枠:12, 24 and 52 weeks

The patient global functioning will be assessed by means of the Clinical Global Impression (CGI) Scales. The Early Clinical Drug Evaluation Program (ECDEU) version of the CGI is a 3-item clinician rated scale that measures illness severity (CGI-S), global improvement or change (CGI-I) and treatment response (efficacy index: CGI-E).

The CGI-S score ranges from 1 (normal) through to 7 (amongst the most severely ill patients).

The calculation of the scores will be performed according to the instructions obtained from copyright holders.

12, 24 and 52 weeks
Patient Global functioning (CGI-I)
時間枠:12, 24 and 52 weeks

The patient global functioning will be assessed by means of the Clinical Global Impression (CGI) Scales. The Early Clinical Drug Evaluation Program (ECDEU) version of the CGI is a 3-item clinician rated scale that measures illness severity (CGI-S), global improvement or change (CGI-I) and treatment response (efficacy index: CGI-E).

The CGI-I score ranges from 1 (very much improved) through to 7 (very much worse).

The calculation of the scores will be performed according to the instructions obtained from copyright holders.

12, 24 and 52 weeks
Patient Global functioning (CGI-E)
時間枠:12, 24 and 52 weeks

The patient global functioning will be assessed by means of the Clinical Global Impression (CGI) Scales. The Early Clinical Drug Evaluation Program (ECDEU) version of the CGI is a 3-item clinician rated scale that measures illness severity (CGI-S), global improvement or change (CGI-I) and treatment response (efficacy index: CGI-E).

The CGI-E score should take account of both therapeutic effect and tolerance, and ranges from 0 (marked improvement and no toxicity) and 4 (unchanged or worse and toxicity outweigh the therapeutic effects). Each component of the CGI is rated separately; the instrument does not yield a global score.

The calculation of the scores will be performed according to the instructions obtained from copyright holders.

12, 24 and 52 weeks
Daytime Sleepiness
時間枠:12, 24 and 52 weeks

Daytime Sleepiness will be assessed by means of the Epworth Sleepiness Scale (ESS). The ESS is a self-administered questionnaire with 8 questions. Respondents are asked to rate, on a 4-point scale (0-3), their usual chances of dozing off or falling asleep while engaged in eight different daily activities. The ESS score can range from 0 to 24. The higher the ESS score, the higher that person Average Sleep Propensity in Daily Life (ASP), or their daytime sleepiness across a wide range of activities in their daily lives.

12, 24 and 52 weeks
Hospital Anxiety and Depression
時間枠:12, 24 and 52 weeks

Anxiety and depression symptoms will be assessed by means of the the Hospital Anxiety and Depression Scale (HADS). This is a patient self-reported instrument consisting of 14 items that provide scores on two specific subscales: "Anxiety" subscale (HADS-A, 7 items) and "Depression" subscale (HADS-D, 7 items).

All items were scored on a 4-point Likert scale from 0 ("never") to 3 ("almost every day") referring to overt symptoms within the last week. Total scores range from 0 to 21 points for each subscale, with higher scores indicating higher levels of symptoms.

12, 24 and 52 weeks
Retention with cenobamate
時間枠:52 weeks

Retention with cenobamate will be assessed by calculating the frequency of patients still on treatment with cenobamate at 52 weeks of treatment initiation.

52 weeks

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2023年1月24日

一次修了 (実際)

2025年12月30日

研究の完了 (実際)

2026年10月21日

試験登録日

最初に提出

2023年4月26日

QC基準を満たした最初の提出物

2023年5月5日

最初の投稿 (実際)

2023年5月16日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月13日

QC基準を満たした最後の更新が送信されました

2026年11月10日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する